Lucy Hicks

Treat-to-Target Approach for RA Improves Time to Pregnancy

The sFlt-1/PlGF ratio did not effectively gauge future preeclampsia risk in pregnant patients with SLE and proteinuria.

Data from recent studies suggested improved risk stratification and understanding of disease pathogenesis are key in identifying more effective medical interventions.

The journal will be part of a new partnership with Elsevier beginning in January 2025.

The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.

Visualizing microvascular changes could aid diagnosis in arthritis, cancer, and peripheral vascular disease, among other potential applications.

ACPA–negative individuals with clinically suspect arthralgia had reduced rates of RA development when treated with a 1-year course of methotrexate, compared with placebo.

This is the fourth ustekinumab biosimilar approval in the United States, with the drug set to launch in 2025.

The drug is the first and only dual IL-17A and IL-17F inhibitor approved to treat four chronic immune-mediated inflammatory diseases.

Christie Bartels discussed how rheumatology clinics can be utilized to tackle two common risk factors for heart disease without adding additional burden onto clinicians.

In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.